Efficiency of coculture with angiogenic cells or physiological BMP-2 administration on improving osteogenic differentiation and bone formation of MSCs.


Journal

Journal of biomedical materials research. Part A
ISSN: 1552-4965
Titre abrégé: J Biomed Mater Res A
Pays: United States
ID NLM: 101234237

Informations de publication

Date de publication:
03 2019
Historique:
received: 04 10 2018
accepted: 15 11 2018
pubmed: 21 11 2018
medline: 28 5 2020
entrez: 21 11 2018
Statut: ppublish

Résumé

Cell-based bone regeneration with mesenchymal stem cells (MSCs) represents the current challenge toward repair of bone defects and fractures. The supposed hurdles for satisfactory performance of cell-based constructs include inadequate vascularization and osteogenic signals. Considering the reported beneficial role of angiogenic cells in promoting vascularization and osteogenic differentiation and the osteogenic potential of bone morphogenetic protein 2 (BMP-2), we here evaluated the efficiency of coculture with angiogenic cells or a physiological dose of BMP-2 on improving osteogenic differentiation of MSCs and bone formation in vivo. In three dimensional (3D) collagen hydrogels in vitro, cocultured human umbilical vein endothelial cells (HUVECs) in a 1:1 ratio or with a physiological dose of BMP-2 (2 ng/μL) promoted the osteogenic potential of MSCs evidenced by enhanced alkaline phosphatase activity and gene expression of osteogenic markers. Notably, HUVECs evoked similar osteogenic stimulation as BMP-2, albeit in a delayed manner. When their bone formation capacity was further evaluated in a mouse subcutaneous implantation model, MSCs with BMP-2 demonstrated the highest efficiency with reproducible bone formation. In contrast, MSCs cocultured with HUVECs constructs displayed substantial blood vessel-like structures with fibrous tissue rather than ectopic bone as MSC monoculture controls. Our findings confirm the priority of generating cell-based bone constructs with physiological BMP-2 administration and indicate the potential of using angiogenic cells to develop vascularized constructs. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 107A: 643-653, 2019.

Identifiants

pubmed: 30458064
doi: 10.1002/jbm.a.36581
doi:

Substances chimiques

BMP2 protein, human 0
Bone Morphogenetic Protein 2 0
Hydrogels 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

643-653

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Yang Zhang (Y)

Department of Biomaterials, Radboudumc, Nijmegen, the Netherlands.

Wanxun Yang (W)

Department of Biomaterials, Radboudumc, Nijmegen, the Netherlands.

Amar Devit (A)

Department of Biomaterials, Radboudumc, Nijmegen, the Netherlands.
Faculty of Medical Science, Radboud University, Nijmegen, the Netherlands.

Jeroen J J P van den Beucken (JJJP)

Department of Biomaterials, Radboudumc, Nijmegen, the Netherlands.
Radboud Institute of Molecular Life Sciences (RIMLS), Theme Reconstructive & Regenerative Medicine, Nijmegen, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH